Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes

NCT02115204 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT02115204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02115204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2000
Completion date
August 31, 2010
Enrollment
2,011 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer